Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia Therapeutics (Nasdaq: AKBA) has announced the granting of stock options to eight newly-hired employees as part of their inducement award program.

Rhea-AI Summary

Akebia Therapeutics (Nasdaq: AKBA) has announced the granting of stock options to eight newly-hired employees as part of their inducement award program. The grants, made on March 31, 2025, total 73,325 shares of common stock with an exercise price of $1.92 per share, matching the closing price on the grant date.

The options feature a four-year vesting schedule, with 25% vesting after the first year and the remaining 75% vesting quarterly thereafter, contingent on continued employment. Each option has a 10-year term and was granted in accordance with Nasdaq Listing Rule 5635(c)(4).

Argus Session date unavailable

-2.59% session move Open Argus

Details

News Market Reaction – AKBA

The recorded move for AKBA in the trading session of this news was -2.59%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics^®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted eight newly-hired employees options to purchase an aggregate of 73,325 shares of Akebia’s common stock on March 31, 2025. The options were granted as an inducement material to each employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

The options have an exercise price of $1.92 per share, which is equal to the closing price of Akebia’s common stock on the grant date. The stock options vest over four years, with 25% of the shares vesting on the first anniversary of the grant date and the remaining 75% of shares vesting quarterly thereafter, in each case, subject to the new employee’s continued service with Akebia. Each stock option has a 10-year term and is subject to the terms and conditions of Akebia’s inducement award program and a stock option agreement covering the grant.

About Akebia Therapeutics

Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.

Akebia Therapeutics Contact

Mercedes Carrasco
mcarrasco@akebia.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares were granted in Akebia Therapeutics' (AKBA) March 2025 inducement grants?

Akebia Therapeutics granted options for 73,325 shares of common stock to eight new employees.

What is the exercise price for AKBA's March 2025 inducement stock options?

The exercise price is $1.92 per share, equal to the closing price on March 31, 2025.

What is the vesting schedule for Akebia's (AKBA) March 2025 inducement grants?

The options vest over 4 years: 25% after first year, remaining 75% quarterly thereafter.

How long is the term of AKBA's March 2025 inducement stock options?

Each stock option has a 10-year term.